Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature.
LokeshwarNKumarLKumariM. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma2005; 46(5): 781–784.
2.
ChngWJTanLH. Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia. Leuk Res2005; 29(6): 719–720.
3.
SumiMTauchiTShimamotoT. Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy. Rinsho Ketsueki2002; 43(9): 868–870.
4.
SrinivasUPillaiLSKumarR. Bone marrow aplasia–a rare complication of imatinib therapy in CML patients. Am J Hematol2007; 82(4): 314–316.
5.
RamRGafter-GviliAOkonE. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?. Acta Haematol2008; 119(2): 104–107.
6.
Quintas-CardamaADe Souza SantosFPKantarjianH. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer2009; 115(17): 3935–3943.
7.
KantarjianHSawyersCHochhausA. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med2002; 346(9): 645–652.
8.
O'BrienSGDeiningerMW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol2003; 40(2 Suppl 2): 26–30.
9.
HasserjianRPBoecklinFParkerS. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol2002; 117(3): 360–367.
10.
KantarjianHCortesJO'BrienS. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph + CML-CP). Proc Am Soc Clin Oncol2002; 21: abstract 1043
11.
TalpazMShahNPKantarjianH. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med2006; 354(24): 2531–2541.
12.
SongMKChoiYJSeolYM. Nilotinib-induced bone marrow aplasia. Eur J Haematol2009; 83(2): 161–162.
13.
KantarjianHMGilesFGattermannN. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood2007; 110(10): 3540–3546.
14.
CortesJEJonesDO'BrienS. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol2010; 28(3): 392–397.
15.
DrukerBJGuilhotFO'BrienSG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006; 355(23): 2408–2417.
16.
DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002; 347(7): 472–480.
17.
DagherRCohenMWilliamsG. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res2002; 8(10): 3034–3038.
18.
BuchdungerEZimmermannJMettH. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- phenylaminopyrimidine derivative. Cancer Res1996; 56(1): 100–104.
19.
Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996; 2: 561–566.
20.
BuchdungerECioffiCLLawN. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther2000; 295(1): 139–145.
21.
DrukerBJLydonNB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest2000; 105(1): 3–7.
22.
DrukerBJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol2003; 40(1): 50–58.
23.
PuttiniMColucciaAMBoschelliF. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res2006; 66(23): 11314–11322.
24.
WeisbergEManleyPWBreitensteinW. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell2005; 7(2): 129–141.
25.
Van EttenRA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol1999; 9(5): 179–186.
26.
WangJY. Regulation of cell death by the Abl tyrosine kinase. Oncogene2000; 19(49): 5643–5650.
27.
LewisJMBaskaranRTaageperaS. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A1996; 93(26): 15174–15179.
28.
RostiVBergamaschiGLucottiC. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood1995; 86(9): 3387–3393.
29.
PetzerALEavesCJBarnettMJ. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood1997; 90(1): 64–69.
30.
BrummendorfTHDragowskaWZijlmansJMJM. Asymmetric cell divisions sustain long-term hematopoiesis from single-sorted human fetal liver cells. J Exp Med1998; 188(6): 1117–1124.
31.
GlimmHEavesCJ. Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture. Blood1999; 94(7): 2161–2168.
32.
SuRJZhangXBLiK. Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances long- term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. Br J Haematol2002; 117(3): 735–746.
33.
BartolovicKBalabanovSHartmannU. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood2004; 103(2): 523–529.
34.
GrahamSMJorgensenHGAllanE. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood2002; 99(1): 319–325.
